Current and emerging monoclonal antibodies for treating familial hypercholesterolemia in children

Area of Science:

• Cardiovascular Medicine
• Genetics
• Pharmacology

Background:

• Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder leading to high LDL-C levels and premature cardiovascular disease risk.
• Early identification and treatment in children are crucial for mitigating long-term health consequences.
• Standard lipid-lowering therapies like statins and ezetimibe are not universally effective for all pediatric HeFH patients.

Purpose of the Study:

• To review current and emerging monoclonal antibody therapies for pediatric HeFH.
• To provide an overview of PCSK9 inhibitors for managing HeFH in children.

Main Methods:

• Literature review of available and investigational monoclonal antibodies for HeFH treatment in children.
• Analysis of safety and efficacy data for PCSK9 inhibitors in pediatric populations.

Main Results:

• PCSK9 inhibitors (evolocumab, alirocumab) are effective and safe for children with HeFH when oral therapies are insufficient or not tolerated.
• Evolocumab is approved for ages 10+, and alirocumab for ages 8+.
• High cost necessitates careful patient selection for these advanced therapies.

Conclusions:

• Monoclonal antibodies, particularly PCSK9 inhibitors, represent a vital therapeutic option for children with HeFH unresponsive to standard treatments.
• The use of these agents requires careful consideration of cost-effectiveness and patient selection.
• Continued research and development in this area are essential for improving outcomes in pediatric cardiovascular health.